Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling

Fig. 4

MYSM1 suppresses CRC cell migration and the EMT process. A and B The metastatic ability of HCT116 cells transfected with siMYSM1/siNC and SW620 cells infected with Lenti-MYSM1/Lenti-NC was tested in wound healing (A) and Transwell (B) assays. Scale bars: 50 μm. The error bars indicate the SDs (*P < 0.05 and **P < 0.01, n = 3 independent experiments). C Morphological observations of cells with MYSM1 knockdown or overexpression under a light microscope. D Expression analysis of six representative EMT biomarkers in HCT116 cells transfected with siMYSM1/siNC and SW620 cells infected with Lenti-MYSM1/Lenti-NC by qRT-PCR. The data are shown as the means ± SDs (*P < 0.05 and **P < 0.01, n = 3 independent experiments). E The protein levels of CDH1 and vimentin in HCT116 cells transfected with siMYSM1/siNC and SW620 cells infected with Lenti-MYSM1/Lenti-NC were analyzed by western blot. F Engineered SW620 cells were injected into the tail veins of athymic BALB/c mice to investigate the metastatic potential of CRC cells. After 6 weeks, the lungs were photographed (left), and the nodules were counted (right). The data are expressed as the means ± SDs (*P < 0.05, n = 3 independent experiments)

Back to article page